Journal of International Oncology

Journal of International Oncology ›› 2019, Vol. 46 ›› Issue (10): 627-630.doi: 10.3760/cma.j.issn.1673-422X.2019.10.013

Previous Articles     Next Articles

Application of stereotactic body radiation therapy in advanced renal cell carcinoma

Cai Liang1, Shen Yali2   

  1. 1Lung Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China; 2Department of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu 610041, China

  • Online:2019-10-08 Published:2019-12-22
  • Contact: Shen Yali, Email: sylprecious@163.com E-mail: sylprecious@163.com
  • Supported by:

    Science and Technology Plan of Sichuan Province of China (2019YJ0142)

PDF

261

Abstract:

Stereotactic body radiation therapy (SBRT) can effectively kill renal cancer cells by biological molecules such as hypoxia-inducible factor-1α and acid sphingomyelinase. SBRT regimen with higher biological dose and single irradiation can achieve more effective local control of primary and metastatic lesion of advanced renal cancer, and adverse reactions can be tolerated. Combination of SBRT and targeted drugs can increase the sensitivity of renal cancer to radiotherapy, and the combination of SBRT and immune drugs can enhance the immune response through the abscopal effect. The efficacy of SBRT in the treatment of advanced renal cancer remains to be explored.

Key words:

Kidney neoplasms, Advanced tumor, Stereotactic body radiation therapy